Clinical trials and ample anecdotal evidence support better antiretroviral therapy (ART) outcomes when HIV resistance testing is performed. This guideline was developed by lead author Dr. Steven M. Fine, with the MCCC, for the NYSDOH AI as a resource for clinicians in New York State who provide care for patients with HIV.
The guideline provides evidence-based recommendations for using HIV drug resistance testing to help improve ART outcomes, with the goals of:
Assisting clinicians in determining when to order HIV drug resistance testing.
Informing clinicians about the different types, benefits, and limitations of currently available resistance assays.
Assisting clinicians in choosing resistance testing to improve treatment outcomes.
On behalf of the NYSDOH AI, lead authors Drs. Judith Griffin, Sara Lorenz Taki, and Timothy Wiegand, with the Substance Use Guidelines Committee, developed this guidance as a resource for clinicians in NYS who provide medical care for patients who use stimulants, with the goals of:
Informing clinicians about different types of stimulants and current terminology for describing stimulants and stimulant use.
Providing strategies for talking with patients about stimulant use and the associated risks, including opioid overdose.
Summarizing the treatment options for stimulant use disorder.
The guidance focuses on nonprescription stimulant substances, including cocaine and crack; methamphetamine, 3,4-methylenedioxy-methamphetamine (MDMA); and synthetic cathinones (bath salts).
Integrating Hepatitis C Treatment into Opioid Treatment Programs: The Greenwich House Story: HCV infection is a major public health problem responsible for substantial morbidity, including cirrhosis and liver cancer, and mortality. In 2021, over 6,500 new cases were reported in New York State, many of which occurred in younger people as a result of injection drug use. Although we have highly effective treatments available for HCV, many people face numerous barriers to accessing them. With the ongoing opioid epidemic fueling new cases, innovative ways of reaching people who inject drugs to ensure they have access to treatment are more essential than ever. Furthermore, people who use drugs and substance use disorder treatment programs were identified in the New York State HCV Elimination Plan as priority populations and settings to focus HCV elimination efforts.
Opioid Treatment Programs, or OTPs for short, are uniquely poised to engage people who inject drugs and integrate HCV treatment into their services and help expand access to those most in need. This episode, featuring Dr. Sara Lorenz Taki from New York City’s Greenwich House, will discuss evidence for and best practices to integrate hepatitis C treatment into an OTP setting. Listen now
If this newsletter was forwarded to you, please subscribe now to make sure you receive the Clinical Guidelines Program news every month and stay current with new and updated guidelines.
Subscribing is as easy as entering your email address. We will send you just 1 email per month, and we do not share our mailing list.
Comment? Question? Suggestion?Drop us a line: [email protected]We welcome feedback and suggestions, and if you send us a question, we will get back to you as quickly as possible. Please note, however, that we cannot answer questions about the care or treatment of specific patients and cannot provide clinical advice.
